Familial ovarian cancer and early ovarian cancer: Biologic, pathologic, and clinical features

International Journal of Gynecological Pathology

Volumn 20, Issue 1, 2001, Pages 48-63

  Werness, Bruce A ^a,c   Eltabbakh, Gamal H ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Familial ovarian cancer; Ovarian cancer screening; Prophylactic oophorectomy

Indexed keywords

CA 125 ANTIGEN;

CANCER FAMILY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER TEST; EARLY CANCER; EARLY DIAGNOSIS; FAMILIAL CANCER; FEMALE; HUMAN; ONCOGENE; OVARIECTOMY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SURVIVAL RATE; TREATMENT INDICATION;

EID: 0035155120     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200101000-00005     Document Type: Review

References (123)

1. The reduction in risk of ovarian cancer associated with oral-contraceptive use: The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
2. Molecular genetics of hereditary ovarian cancer
3. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: No evidence for other ovarian cancer-susceptibility genes
4. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
5. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium
6. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]
7. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
8. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
9. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds [see comments]
10. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
11. Expression of BRCA1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice [published erratum appears in Genes Dev 1996 Feb I;10:365]
12. Murine BRCA2: Sequeine BRCA2: Sequence, map position, and expression pattern
13. Transcriptional activation functions in BRCA2
14. Transcriptional activation by BRCA1
15. BRCA1 is a component of the RNA polymerase II holoenzyme
16. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1
17. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1
18. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains
19. Association of BRCA1 with RAD51 in mitotic and meiotic cells
20. RAD51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein [published erratum appears in Cell 1992;71:following 180]
21. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells
22. Embryonic lethality and radiation hypersensitivity mediated by RAD51 in mice lacking BRCA2 [see comments]
23. BRCA1 required for transcription-coupled repair of oxidative DNA damage
24. Inactivation of the mouse BRCA1 gene leads to failure in the morphogenesis of the egg cylinder in early post-implantation development
25. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of BRCA1, BRCA2, BRCA1/BRCA2, BRCA1/P53, and BRCA2/p53 nullizygous embryos
26. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse
27. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations
28. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers
29. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast turnouts
30. Location of BRCA1 in human breast and ovarian cancer cells
31. Aberrant subcellular localization of BRCA1 in breast cancer [see comments] [published erratum appears in Science 1995;270:1424]
32. BRCA1 is secreted and exhibits properties of a granin
33. BRCA1 protein products: Antibody specificity
34. The carrier frequency of the BRCA1 185de1AG mutation is approximately 1% in Ashkenazi Jewish individuals [see comments] [published erratum appears in Nat Genet 1996 Jan;12:110]
35. The carrier frequency of the BRCA2 6174de1T mutation among Ashkenazi Jewish individuals is approximately 1%
36. Germline mutations in the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation
37. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene
38. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer
39. BRCA1 mutations in primary breast and ovarian carcinomas
40. Mutation analysis of the BRCA1 gene in ovarian cancers
41. Loss Of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype
42. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: A correlation with other biological parameters
43. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas
44. BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism? [editorial; comment]
45. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
46. Mutations at BRCA1: The medullary breast carcinoma revisited
47. Tumour biological features of BRCA1-induced breast and ovarian cancer
48. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
49. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study
50. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden [see comments]
51. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
52. Characteristics of genetically determined ovarian cancer
53. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer
54. Histology of BRCA1-associated ovarian tumours
55. Clinical and genetic evaluation of thirty ovarian cancer families
56. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers: With emphasis on methodology
57. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications
58. Histopathology of familial ovarian tumors in women from families with and without germ-line BRCA1 mutations
59. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1
60. Familial ovarian cancer: Increasing in frequency?
61. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome
62. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families
63. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry
64. Serous carcinoma of the peritoneum after oophorectomy
65. Hereditary ovarian cancer: Heterogeneity in age at diagnosis
66. Familial ovarian carcinoma: Clinical nuances
67. Papillary peritoneal carcinomatosis after prophylactic oophorectomy
68. Papillary intraperitoneal neoplasia resembling ovarian carcinoma after removal of benign ovaries
69. Effectiveness of prophylactic oophorectomy in inherited breast/ovarian cancer families
70. Compliance with hormone therapy
71. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer
72. Laparoscopic management of women with a family history of ovarian cancer
73. The role of prophylactic oophorectomy in the avoidance of ovarian cancer
74. Ovarian cancer in women with prior hysterectomy: A 14-year experience at the University of Miami [see comments]
75. The residual ovary syndrome
76. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma
77. Current concepts in epithelial ovarian tumors: Does benign to malignant transformation ever occur?
78. Early de novo ovarian carcinoma: A study of 14 cases
79. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations
80. Potential role of the inactivated X chromosome in ovarian epithelial tumor development
81. Early de novo ovarian cancer developing in benign ovarian lesions
82. The behavior of serous tumors of low malignant potential: Are they ever malignant?
83. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer
84. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors
85. Interactive morphometric procedures and statistical analysis in the diagnosis of ovarian dysplasia and carcinoma
86. Characterization of ovarian dysplasia by interactive morphometry
87. Interactive morphometry of normal and hyperplastic peritoneal mesothelial cells and dysplastic and malignant ovarian cells
88. Ovarian dysplasia: Nuclear texture analysis
89. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma
90. Ovarian dysplasia in epithelial inclusion cysts: A morphometric approach using neural networks
91. Morphologic precursors of ovarian epithelial tumors
92. Contralateral ovary in unilateral ovarian carcinoma: A search for preneoplastic lesions
93. Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis
94. Is ovarian cancer associated with an increased frequency of germinal inclusion cysts?
95. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy
96. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies
97. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes
98. Benign ovarian surface epithelium in BRCA-1 positive women
99. Six families prone to ovarian cancer
100. Ovarian dysplasia. A study of identical twins
101. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Res (UKCCCR) Familial Ovarian Cancer Study Group
102. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer
103. Histopathologocal characteristics of prophylactic oophorectomy specimens from women with inherited risk of ovarian cancer
104. Ovarian dysplasia in prophylactic oophorectomy specimens - Cytogenetic and morphometric correlations
105. Ovarian cancer diagnosis: Results of a national ovarian cancer survey
106. The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary
107. Pain in ovarian cancer patients: Prevalence, characteristics, and associated symptoms
108. Delay in diagnosis of epithelial ovarian cancer
109. Clinical picture of women with early stage ovarian cancer
110. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients
111. 125 Tumour-associated antigen: A review of the literature
112. Serum CA-125 measurements > 65 U/mL: Clinical value [see comments]
113. Ovarian cancer screening in asymptomatic postmenopausal women
114. A morphology index based on sonographic findings in ovarian cancer
115. Transabdominal ultrasound screening for early ovarian cancer
116. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer
117. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography [see comments]
118. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer
119. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography
120. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer
121. Psychological impact of screening for familial ovarian cancer
122. Ovarian cancer. Screening, treatment, and follow-up: NIH consensus development panel on ovarian cancer